Nano-enabled delivery systems across the blood-brain barrier

Archives of Pharmacal Research

Volumn 37, Issue 1, 2014, Pages 24-30

  Hwang, Seung Rim ^a   Kim, Kwangmeyung ^b  

^a Chosun University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Blood brain barrier; Central nervous system; Nano enabled delivery; Nanotechnology; Receptor mediated transcytosis

Indexed keywords

NANOMATERIAL; CELL SURFACE RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIER; NANOPARTICLE;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DIFFUSION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS ADMINISTRATION; MEMBRANE PERMEABILITY; NANOENABLED DELIVERY SYSTEM; NANOENCAPSULATION; NANOTECHNOLOGY; REVIEW; ANIMAL; CHEMISTRY; DEVICES; HUMAN; METABOLISM; NANOMEDICINE; PERMEABILITY; PHARMACEUTICS; PROCEDURES; TRANSCYTOSIS;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; PERMEABILITY; RECEPTORS, CELL SURFACE; TECHNOLOGY, PHARMACEUTICAL; TRANSCYTOSIS;

EID: 84892925252     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0272-6     Document Type: Review

References (73)

1. Abbott, N.J., and I.A. Romero. 1996. Transporting therapeutics across the blood-brain barrier. Molecular Medicine Today 2: 106-113.
2. Abbott, N.J., L. Ronnback, and E. Hansson. 2006. Astrocyteendothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience 7: 41-53.
3. Allemann, E., P. Gravel, J.C. Leroux, L. Balant, and R. Gurny. 1997. Kinetics of blood component adsorption on poly(D, L-lactic acid) nanoparticles: Evidence of complement C3 component involvement. Journal of Biomedical Materials Research 37: 229-234.
4. Aller, S.G., J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, and G. Chang. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
5. Alyautdin, R., D. Gothier, V. Petrov, D. Kharkevich, and J. Kreuter. 1995. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 41: 44-48.
6. Alyautdin, R.N., V.E. Petrov, K. Langer, A. Berthold, D.A. Kharkevich, and J. Kreuter. 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research 14: 325-328.
7. Ballabh, P., A. Braun, and M. Nedergaard. 2004. The blood-brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiology of Disease 16: 1-13.
8. Barbu, E., E. Molnar, J. Tsibouklis, and D.C. Gorecki. 2009. The potential for nanoparticle-based drug delivery to the brain: Overcoming the blood-brain barrier. Expert Opinion on Drug Delivery 6: 553-565.
9. Bartus, R.T., P. Snodgrass, J. Marsh, M. Agostino, A. Perkins, and D.F. Emerich. 2000. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. The Journal of Pharmacology and Experimental Therapeutics 293: 903-911.
10. Baumann, M.D., C.E. Kang, C.H. Tator, and M.S. Shoichet. 2010. Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials 31: 7631-7639.
11. Begley, D.J. 2004. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacology Therapeut 104: 29-45.
12. Begley, D.J., and M.W. Brightman. 2003. Structural and functional aspects of the blood-brain barrier. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques 61: 39-78.
13. Brigger, I., J. Morizet, G. Aubert, H. Chacun, M.J. Terrier-Lacombe, P. Couvreur, and G. Vassal. 2002. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. Journal of Pharmacology and Experimental Therapeutics 303: 928-936.
14. Butt, A.M., H.C. Jones, and N.J. Abbott. 1990. Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study. The Journal of Physiology 429: 47-62.
15. Dakwar, G.R., I. Abu Hammad, M. Popov, C. Linder, S. Grinberg, E. Heldman, and D. Stepensky. 2012. Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. The Journal of Controlled Release 160: 315-321.
16. Deli, M.A. 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochimica et Biophysica Acta 1788: 892-910.
17. Dempsey, E.W., and G.B. Wislocki. 1955. An electron microscopic study of the blood-brain barrier in the rat, employing silver nitrate as a vital stain. The Journal of Biophysical and Biochemical Cytology 1: 245-256.
18. Devries, H.E., J. Kuiper, A.G. Deboer, T.J.C. Vanberkel, and D.D. Breimer. 1997. The blood-brain barrier in neuroinflammatory diseases. Pharmacological Reviews 49: 143-155.
19. Duffy, K.R., and W.M. Pardridge. 1987. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Research 420: 32-38.
20. El-Bacha, R.S., and A. Minn. 1999a. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cellular and Molecular Biology (Noisy-le-grand) 45: 15-23.
21. El-Bacha, R.S., and A. Minn. 1999b. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cellular and Molecular Biology 45: 15-23.
22. Emerich, D.F., R.L. Dean, J. Marsh, M. Pink, D. Lafreniere, P. Snodgrass, and R.T. Bartus. 2000. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharmaceutical Research 17: 1212-1219.
23. Fabel, K., J. Dietrich, P. Hau, C. Wismeth, B. Winner, S. Przywara, A. Steinbrecher, W. Ullrich, and U. Bogdahn. 2001. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92: 1936-1942.
24. Ford, J.M. 1996. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. European Journal of Cancer 32A: 991-1001.
25. Friese, A., E. Seiller, G. Quack, B. Lorenz, and J. Kreuter. 2000. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. European Journal of Pharmaceutics and Biopharmaceutics 49: 103-109.
26. Gabathuler, R. 2010. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease 37: 48-57.
27. Gaillard, P.J. 2011. Case study: To-BBB's G-technology, getting the best from drug-delivery research with industry-academia partnerships. Therapeutic Delivery 2: 1391-1394.
28. Golden, P.L., T.J. Maccagnan, and W.M. Pardridge. 1997. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. The Journal of Clinical Investigation 99: 14-18.
29. Gulyaev, A.E., S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, and J. Kreuter. 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research 16: 1564-1569.
30. Guo, N., C. Mcintosh, and C. Shaw. 1992. Glutathione: New candidate neuropeptide in the central nervous system. Neuroscience 51: 835-842.
31. Hau, P., K. Fabel, U. Baumgart, P. Rummele, O. Grauer, A. Bock, C. Dietmaier, W. Dietmaier, J. Dietrich, C. Dudel, F. Hubner, T. Jauch, E. Drechsel, I. Kleiter, C. Wismeth, A. Zellner, A. Brawanski, A. Steinbrecher, J. Marienhagen, and U. Bogdahn. 2004. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100: 1199-1207.
32. Hu, K., Y. Shi, W. Jiang, J. Han, S. Huang, and X. Jiang. 2011. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease. International Journal of Pharmaceutics 415: 273-283.
33. Huwyler, J., D. Wu, and W.M. Pardridge. 1996. Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences USA 93: 14164-14169.
34. Jefferies, W.A., M.R. Brandon, S.V. Hunt, A.F. Williams, K.C. Gatter, and D.Y. Mason. 1984. Transferrin receptor on endothelium of brain capillaries. Nature 312: 162-163.
35. Jones, A.R., and E.V. Shusta. 2007. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceutical Research 24: 1759-1771.
36. Joo, F. 1987. The blood-brain-barrier. Nature 329: 208.
37. Juillerat-Jeanneret, L. 2008. The targeted delivery of cancer drugs across the blood-brain barrier: Chemical modifications of drugs or drug-nanoparticles? Drug Discovery Today 13: 1099-1106.
38. Kannan, R., R. Chakrabarti, D. Tang, K.J. Kim, and N. Kaplowitz. 2000. GSH transport in human cerebrovascular endothelial cells and human astrocytes: Evidence for luminal localization of Na?-dependent GSH transport in HCEC. Brain Research 852: 374-382.
39. Kreuter, J. 2001. Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews 47: 65-81.
40. Kreuter, J., R.N. Alyautdin, D.A. Kharkevich, and A.A. Ivanov. 1995. Passage of peptides through the blood-brain-barrier with colloidal polymer particles (nanoparticles). Brain Research 674: 171-174.
41. Kuo, Y.C., and C.L. Lee. 2012. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloid Surface B 90: 75-82.
42. Lanius, R.A., C.A. Shaw, R. Wagey, and C. Krieger. 1994. Characterization, distribution, and protein kinase C-mediated regulation of [35S]glutathione binding sites in mouse and human spinal cord. Journal of Neurochemistry 63: 155-160.
43. Lockman, P.R., R.J. Mumper, M.A. Khan, and D.D. Allen. 2002. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Development and Industrial Pharmacy 28: 1-13.
44. Mayer, U., E. Wagenaar, J.H. Beijnen, J.W. Smit, D.K.F. Meijer, J. Vanasperen, P. Borst, and A.H. Schinkel. 1996. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. British Journal of Pharmacology 119: 1038-1044.
45. Mensch, J., J. Oyarzabal, C. Mackie, and P. Augustijns. 2009. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. Journal of Pharmaceutical Sciences 98: 4429-4468.
46. Olivier, J.C. 2005. Drug transport to brain with targeted nanoparticles. The Journal of the American Society for Experimental Neuro Therapeutics 2: 108-119.
47. Palmer, A.M., and F.A. Stephenson. 2005. CNS drug discovery: Challenges and solutions. Drug News and Perspectives 18: 51-57.
48. Pang, Z., W. Lu, H. Gao, K. Hu, J. Chen, C. Zhang, X. Gao, X. Jiang, and C. Zhu. 2008. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. The Journal of Controlled Release 128: 120-127.
49. Papadopoulos, M.C., S. Saadoun, D.C. Davies, and B.A. Bell. 2001. Emerging molecular mechanisms of brain tumour oedema. British Journal of Neurosurgery 15: 101-108.
50. Pardridge, W.M. 2002. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discovery Today 7: 5-7.
51. Pardridge, W.M. 2003. Blood-brain barrier drug targeting: The future of brain drug development. Molecular Interventions 3: 90-105.
52. Pardridge, W.M. 2007. Drug targeting to the brain. Pharmaceutical Research 24: 1733-1744.
53. Pardridge, W.M. 2010. Biopharmaceutical drug targeting to the brain. Journal of Drug Targeting 18: 157-167.
54. Patel, M.M., B.R. Goyal, S.V. Bhadada, J.S. Bhatt, and A.F. Amin. 2009. Getting into the brain approaches to enhance brain drug delivery. Central Nervous System Drugs 23: 35-58.
55. Pathan, S.A., Z. Iqbal, S.M. Zaidi, S. Talegaonkar, D. Vohra, G.K. Jain, A. Azeem, N. Jain, J.R. Lalani, R.K. Khar, and F.J. Ahmad. 2009. CNS drug delivery systems: Novel approaches. Recent Patents on Drug Delivery and Formulation 3: 71-89.
56. Popov, M., S. Grinberg, C. Linder, T. Waner, B. Levi-Hevroni, R.J. Deckelbaum, and E. Heldman. 2012. Site-directed decapsulation of bolaamphiphilic vesicles with enzymatic cleavable surface groups. The Journal of Controlled Release 160: 306-314.
57. Popov, M., C. Linder, R.J. Deckelbaum, S. Grinberg, I.H. Hansen, E. Shaubi, T. Waner, and E. Heldman. 2010. Cationic vesicles from novel bolaamphiphilic compounds. Journal of Liposome Research 20: 147-159.
58. Ranganath, S.H., Y. Fu, D.Y. Arifin, I. Kee, L. Zheng, H.S. Lee, P.K. Chow, and C.H. Wang. 2010. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 31: 5199-5207.
59. Ranganathan, R., S. Madanmohan, A. Kesavan, G. Baskar, Y.R. Krishnamoorthy, R. Santosham, D. Ponraju, S.K. Rayala, and G. Venkatraman. 2012. Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications. International Journal of Nanomedicine 7: 1043-1060.
60. Reese, T.S., and M.J. Karnovsky. 1967. Fine structural localization of a blood-brain barrier to exogenous peroxidase. The Journal of Cell Biology 34: 207-217.
61. Ren, J., S. Shen, D. Wang, Z. Xi, L. Guo, Z. Pang, Y. Qian, X. Sun, and X. Jiang. 2012. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33: 3324-3333.
62. Schneider, S.W., T. Ludwig, L. Tatenhorst, S. Braune, H. Oberleithner, V. Senner, and W. Paulus. 2004. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathologica 107: 272-276.
63. Silva, G.A. 2008. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neuroscience 9(Suppl 3): S4. doi:10.1186/1471-2202-9-S3-S4.
64. Soni, V., D.V. Kohli, and S.K. Jain. 2005. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. Journal of Drug Targeting 13: 245-250.
65. Soppimath, K.S., T.M. Aminabhavi, A.R. Kulkarni, and W.E. Rudzinski. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. The Journal of Controlled Release 70: 1-20.
66. Sun, X., Z. Pang, H. Ye, B. Qiu, L. Guo, J. Li, J. Ren, Y. Qian, Q. Zhang, J. Chen, and X. Jiang. 2012. Co-delivery of pEGFPhTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 33: 916-924.
67. Tamai, I., Y. Sai, H. Kobayashi, M. Kamata, T. Wakamiya, and A. Tsuji. 1997. Structure-internalization relationship for adsorptivemediated endocytosis of basic peptides at the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics 280: 410-415.
68. Vlieghe, P., and M. Khrestchatisky. 2010. Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system. Therapeutic Delivery 1: 489-494.
69. Wen, Z., Z. Yan, R. He, Z. Pang, L. Guo, Y. Qian, X. Jiang, and L. Fang. 2011. Brain targeting and toxicity study of odorranalectinconjugated nanoparticles following intranasal administration. Drug Delivery 18: 555-561.
70. Wissing, S.A., O. Kayser, and R.H. Muller. 2004. Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug Delivery Reviews 56: 1257-1272.
71. Wolburg, H., and A. Lippoldt. 2002. Tight junctions of the blood-brain barrier: Development, composition and regulation. Vascular Pharmacology 38: 323-337.
72. Xin, H., X. Sha, X. Jiang, L. Chen, K. Law, J. Gu, Y. Chen, X. Wang, and X. Fang. 2012. The brain targeting mechanism of Angiopepconjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles. Biomaterials 33: 1673-1681.
73. Zhang, Q.Z., L.S. Zha, Y. Zhang, W.M. Jiang, W. Lu, Z.Q. Shi, X.G. Jiang, and S.K. Fu. 2006. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. Journal of Drug Targeting 14: 281-290.